A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
1/21/2026
DealsNewsletterRefractive
2025 in Review: STAAR Calls Off Alcon Acquisition Deal after Failed Vote by Shareholders
STAAR Surgical’s termination this month of its acquisition agreement with Alcon ended a five-month saga that pivoted on how the ophthalmic industry should valuate the world’s leading phakic IOL mak...
1/21/2026
AcquisitionsDealsFundingNewsletter
Venture Capital in Ophthalmology Doubled in 2025 to Just Under $2 Billion
Venture capital investment in ophthalmology more than doubled from 2024 to 2025, totaling just under $2 billion in 2025 compared to $934.1 million in 2024. 2025 saw $1.1 billion in early-stage fund...
1/21/2026
Clinical TrialNewsletterRegulationRetina
Ocular Therapeutix Takes Cue from FDA, Will Submit NDA for Axpaxli After Single Phase III Trial
Ocular Therapeutix announced Dec. 8 that it planned to submit a new drug application (NDA) to the US FDA for Axpaxli in wet age-related macular degeneration (AMD) if it sees positive one-year data ...
1/21/2026
Clinical TrialNewsletterRegulationUveitis
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
1/21/2026
DiagnosticNewsletterRegulation
Select US FDA Approvals and Clearances in December 2025
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in December 2025, according to the agency’s database. Remidio received clearance for its Fundus O...
1/21/2026
Clinical TrialNewsletterThyroid Eye Disease
Argenx Pulls Plug on Thyroid Eye Disease Program on Recommendation of Data Monitors
Dutch drugmaker Argenx reported Dec. 15 that it would discontinue the Phase III program for subcutaneous efgartigimod in moderate to severe thyroid eye disease (TED). An independent data monitoring...
1/21/2026
NewsletterRegulationRetina
US FDA Rejects Outlook’s Lytenava for a Third Time, Citing Lack of Efficacy
Outlook Therapeutics reported Dec. 31 that the US FDA had issued a third complete response letter rejecting the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation...
1/21/2026
GlaucomaMeetingNewsletter
Meet with Market Scope at the 2026 Glaucoma 360 Meeting
Market Scope will be presenting industry data at the 2026 Glaucoma 360 meeting, set for Jan. 29-31 in San Francisco. Contact us to set up a time to discuss your custom research needs. Reach us at 3...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.